The genotec-frankfurt.de focus of the industry on living beings that are human and highly controlled standards create unique considerations for business leaders. These characteristics make the industry an ideal place to foster innovation. They have resulted in major breakthroughs biofuels, agricultural yields and life-saving pharmaceuticals.
When it comes to strategies that generate revenue biotech start-ups have numerous options. The majority opt for a technology partnership or an asset-creation-and-out-licensing strategy. Technology partnering can result in higher revenue and lower risk to the financials, whereas strategies for asset creation and outlicensing are able to yield much more returns. A increasing number of biotechs in the research stage employ a hybrid strategy that combines two strategies.
Those who opt for a product-oriented development strategy will succeed commercially in the event that they can bring their pipeline to the right stage and find a pharmaceutical partner or an investor with deep pockets. This is expensive however, and the balance of opportunistic strategies to leverage external resources with scientific decision-making about projects that are homegrown is vital.
Another option is the «platform» model can provide an alternative way to earn revenue. It is less expensive than product-oriented research, but has a significant risk. In this model, a biotech owns and develops its platform technology, before joining with major pharma companies to develop a portfolio of drug discovery projects that focus on specific disease areas (i.e., disease x in biology y). Advinus Therapeutics, among others have adopted this strategy.